Literature DB >> 17855337

Granzyme B-induced cell death involves induction of p53 tumor suppressor gene and its activation in tumor target cells.

Franck Meslin1, Jerome Thiery, Catherine Richon, Abdelali Jalil, Salem Chouaib.   

Abstract

In this study we investigated the involvement of p53 in cytotoxic T-lymphocyte (CTL)-induced tumor target cell killing mediated by the perforin/granzymes pathway. For this purpose we used a human CTL clone (LT12) that kills its autologous melanoma target cells (T1), harboring a wild type p53. We demonstrated initially that LT12 kills its T1 target in a perforin/granzymes-dependent manner. Confocal microscopy and Western blot analysis indicated that conjugate formed between LT12 and T1 resulted in rapid cytoplasmic accumulation of p53 and its activation in T1 target cells. Cytotoxic assay using recombinant granzyme B (GrB) showed that this serine protease is the predominant factor inducing such accumulation. Furthermore, RNA interference-mediated lowering of the p53 protein in T1 cells or pifithrin-alpha-induced p53-specific inhibition activity significantly decreased CTL-induced target killing mediated by CTL or recombinant GrB. This emphasizes that p53 is an important determinant in granzyme B-induced apoptosis. Our data show furthermore that when T1 cells were treated with streptolysin-O/granzyme B, specific phosphorylation of p53 at Ser-15 and Ser-37 residues was observed subsequent to the activation of the stress kinases ataxia telangiectasia mutated (ATM) and p38K. Treatment of T1 cells with pifithrin-alpha resulted in inhibition of p53 phosphorylation at these residues and in a significant decrease in GrB-induced apoptotic T1 cell death. Furthermore, small interference RNAs targeting p53 was also accompanied by an inhibition of streptolysin-O/granzyme B-induced apoptotic T1 cell death. The present study supports p53 induction after CTL-induced stress in target cells. These findings provide new insight into a potential role of p53 as a component involved in the dynamic regulation of the major pathway of CTL-mediated cell death and may have therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855337     DOI: 10.1074/jbc.M705290200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells.

Authors:  Nafiseh Paydarnia; Shahryar Khoshtinat Nikkhoi; Azita Fakhravar; Mohsen Mehdiabdol; Hedieh Heydarzadeh; Saeed Ranjbar
Journal:  Mol Biol Rep       Date:  2019-04-01       Impact factor: 2.316

2.  Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergence.

Authors:  Houssem Benlalam; Thibault Carré; Abdelali Jalil; Zaeem Noman; Bernard Caillou; Philippe Vielh; Andrés Tittarelli; Caroline Robert; Salem Chouaib
Journal:  J Mol Med (Berl)       Date:  2013-06-07       Impact factor: 4.599

3.  Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.

Authors:  David Quigley; Laxmi Silwal-Pandit; Ruth Dannenfelser; Anita Langerød; Hans Kristian Moen Vollan; Charles Vaske; Josie Ursini Siegel; Olga Troyanskaya; Suet-Feung Chin; Carlos Caldas; Allan Balmain; Anne-Lise Børresen-Dale; Vessela Kristensen
Journal:  Mol Cancer Res       Date:  2014-10-28       Impact factor: 5.852

4.  hSMG-1 is a granzyme B-associated stress-responsive protein kinase.

Authors:  Franck Meslin; Ahmed Hamaï; Bernhard Mlecnik; Filippo Rosselli; Catherine Richon; Abdelali Jalil; Gregory Wemhoff; Jerome Thiery; Jerome Galon; Salem Chouaib
Journal:  J Mol Med (Berl)       Date:  2011-02-08       Impact factor: 4.599

5.  Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53.

Authors:  A R M Ruhul Amin; Dongsheng Wang; Hongzheng Zhang; Shifang Peng; Hyung Ju C Shin; Johann C Brandes; Mourad Tighiouart; Fadlo R Khuri; Zhuo Georgia Chen; Dong M Shin
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

6.  Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer.

Authors:  Hong Kyu Lee; Hyeong-Jin Ji; Sang-Kyung Shin; Jihye Koo; Tae Hun Kim; Cho-Won Kim; Yeon Hee Seong; Jun-Eui Park; Kyung-Chul Choi
Journal:  Cancer Immunol Immunother       Date:  2022-01-31       Impact factor: 6.630

7.  Role of perforin-mediated cell apoptosis in murine models of infusion-induced bone marrow failure.

Authors:  Annahita K Sarcon; Marie J Desierto; Wenjun Zhou; Valeria Visconte; Federica Gibellini; Jichun Chen; Neal S Young
Journal:  Exp Hematol       Date:  2009-02-12       Impact factor: 3.084

8.  Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.

Authors:  Sang-Soo Kim; Joe B Harford; Manish Moghe; Antonina Rait; Kathleen F Pirollo; Esther H Chang
Journal:  Nucleic Acids Res       Date:  2018-02-16       Impact factor: 16.971

9.  A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.

Authors:  Sang-Soo Kim; Joe B Harford; Manish Moghe; Tiffani Slaughter; Caroline Doherty; Esther H Chang
Journal:  Int J Cancer       Date:  2019-07-08       Impact factor: 7.396

10.  Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor.

Authors:  Sang-Soo Kim; Joe B Harford; Manish Moghe; Antonina Rait; Esther H Chang
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.